EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound

Were R Omange, Benjamin D Varco-Merth, Omo Fadeyi, Alejandra Marenco, Hiroshi Takata, Derick M Duell, William D Goodwin, Paula Armitage, Christine M Fennessey, Emek Kose, Taina T Immonen, Ewelina Kosmider und 18 weitere

Journal of Clinical Investigation · 16.03.2026 · 136 (6)

DOI: 10.1172/jci198294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 29.01.2026. Verfasst von Were R Omange und 29 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Gene Therapy Institute and. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Simian Immunodeficiency Virus, Simian Acquired Immunodeficiency Syndrome, SAIDS Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, Gilled Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HIV/SIV-specific CD8 + T cell responses are typically unable to control viral rebound following antiretroviral therapy (ART) interruption (ATI). To investigate whether enhancing the magnitude and activation of SIV-specific CD8 + T cells at the time of ATI can improve the immune interception of reactivating SIV infections, we vaccinated SIVmac239-infected rhesus macaques (RMs) on ART, boosting immediately prior to ATI, with a nucleoside-unmodified mRNA vaccine expressing SIVmac239 Gag (mRNA/SIVgag) alone or in combination with Nef (mRNA/SIVnef) and Pol (mRNA/SIVpol). The mRNA/SIVgag vaccine was effective in boosting Gag-specific CD8 + T cells in blood and lymphoid tissues. Following ATI, the mRNA/SIVgag vaccine group showed a significant delay in time to measurable viral rebound compared with controls and manifested lower plasma viral loads (PVLs) for up to 6 weeks after rebound. Similarly, RMs that received mRNA/SIVgag, mRNA/SIVnef, and mRNA/SIVpol also manifested a delay in SIV rebound compared with controls, suggesting that boosting SIV-specific CD8 + T cells during ATI can enhance early immune targeting of reactivating SIV infections. However, viral control was not sustained long term as PVLs were similar across vaccinees and controls by 24 weeks after rebound, highlighting the need for adjunctive therapies to improve the durability of virologic control elicited by CD8 + T cell–targeting vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesSimian Immunodeficiency VirusSimian Acquired Immunodeficiency SyndromeSAIDS VaccinesAnti-Retroviral AgentsAnimalsMacaca mulattaViral LoadGene Products, gagTreatment Interruption

Stichwörter der Autor:innen

AIDS vaccineAIDS/HIVAdaptive immunityImmunology

Substanzen

SAIDS VaccinesAnti-Retroviral AgentsGene Products, gag

Autor:innen und Institutionen

  • Vaccine and Gene Therapy Institute and.
  • Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
  • AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • CureVac SE, Tübingen, Germany.

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • Gilled Sciences
  • National Institute of Allergy and Infectious Diseases
  • NIH Office of the Director
  • National Cancer Institute

Zitieren

APA

Omange, W. R., Varco-Merth, B. D., Fadeyi, O., Marenco, A., Takata, H., Duell, D. M., Goodwin, W. D., Armitage, P., Fennessey, C. M., Kose, E., Immonen, T. T., Kosmider, E., Bosche, W. J., Fast, R., Homick, C., Oswald, K., Shoemaker, R., Bochart, R., MacAllister, R., …, & Okoye, A. A. (2026). Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound. Journal of Clinical Investigation, 136(6). https://doi.org/10.1172/jci198294

Vancouver

Omange WR, Varco-Merth BD, Fadeyi O, Marenco A, Takata H, Duell DM, et al. Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound. Journal of Clinical Investigation. 2026;136(6). doi:10.1172/jci198294

BibTeX
@article{Omange2026,
  author = {Omange, Were R and Varco-Merth, Benjamin D and Fadeyi, Omo and Marenco, Alejandra and Takata, Hiroshi and Duell, Derick M and Goodwin, William D and Armitage, Paula and Fennessey, Christine M and Kose, Emek and Immonen, Taina T and Kosmider, Ewelina and Bosche, William J and Fast, Randy and Homick, Chris and Oswald, Kelli and Shoemaker, Rebecca and Bochart, Rachele and MacAllister, Rhonda and Labriola, Caralyn S and Smedley, Jeremy V and Axthelm, Michael K and Edlefsen, Paul T and Keele, Brandon F and Lifson, Jeffrey D and Gergen, Janina and Petsch, Benjamin and Rauch, Susanne and Picker, Louis J and Okoye, Afam A},
  title = {Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {6},
  doi = {10.1172/jci198294}
}
Kostenlos starten →